

①1 Publication number:

0 357 391
A2

①2

EUROPEAN PATENT APPLICATION

②1 Application number: 89308753.6

②2 Date of filing: 30.08.89

⑤1 Int. Cl.⁵: **C 12 N 15/70**
C 12 N 1/21, C 12 P 21/02,
C 12 N 15/16
/(C12N1/21,C12R1:19)

③0 Priority: 31.08.88 US 239145 18.08.89 US 395797

④3 Date of publication of application:
07.03.90 Bulletin 90/10

⑥4 Designated Contracting States:
AT BE CH DE ES FR GB IT LI NL SE

⑦1 Applicant: **ALLELIX INC.**
6850 Goreway Drive
Mississauga Ontario, L4V 1P1 (CA)

⑦2 Inventor: **Wong, Raymond W. K.**
6903 Edenwood Drive
Mississauga Ontario L5N 4V6 (CA)

Sutherland, Margaret L.
3700 Kanef Cres. Apt. 2312
Mississauga Ontario L5N 4B8 (CA)

⑦4 Representative: **Hildyard, Edward Martin et al**
Frank B. Dehn & Co. European Patent Attorneys Imperial
House 15-19 Kingsway
London WC2B 6UZ (GB)

⑤4 Excretion of heterologous proteins from *E. Coli*.

⑤7 A recombinant DNA construct useful for obtaining excretion from *E. coli* of a heterologous protein, said construct comprising a coding region in which DNA coding for the heterologous protein is coupled in reading frame with DNA coding for the OmpA signal peptide to enable secretion of the protein to the periplasm; and a control region linked operably with the coding region to enable expression thereof in an *E. coli* host, said control region comprising the tac promoter, the lac operator and a consensus ribosome binding site.

EP 0 357 391 A2

Description

EXCRETION OF HETEROLOGOUS PROTEINS FROM E. COLI

This invention relates to the art of genetic engineering as applied to *Escherichia coli*. More particularly, the invention relates to generally engineered *E. coli* cells that excrete heterologous proteins to the medium in which those cells are cultured.

BACKGROUND OF THE INVENTION

Techniques are now well established for directing *E. coli*-produced heterologous proteins across the inner membrane of the *E. coli* cell envelope, into a space between the inner and the outer membrane known as the periplasm. It has been shown that when a protein is expressed as a fusion protein, having an *E. coli*-recognized peptide or "signal peptide" attached to its N-terminus, the desired protein is secreted into the periplasm (see EP 177,343 Genentech Inc.). Several such signal peptides have now been identified by amino acid and DNA sequence (see Watson, M. Nucleic Acids Research, Vol. 12, No. 13, 1984, pp. 5145-5164) and have been used successfully to direct heterologous proteins into the *E. coli* periplasm (see Oka et al, Proc. Natl. Acad. Sci. USA, Vol 82, pp 7212-7216, November 1985 in which human epidermal growth factor (hEGF) was fused with the signal peptide of *E. coli* alkaline phosphatase to direct mature EGF into the *E. coli* periplasm; and see Hsiung et al, Biotechnology, Vol 4, November 1986, pp 991-995 where human growth hormone was directed into the *E. coli* periplasm using the signal peptide of outer membrane protein A (*ompA*) of *E. coli*).

While these periplasmic proteins are often described as "secreted" it should be understood that they are contained intracellularly by the outer membrane and, because they are not available in the medium, can be recovered only once the outer membrane is either disrupted or "permeabilized" to release the periplasmic components.

To facilitate the protein recovery process it is preferable that the protein accumulates in the culture medium during culturing of the protein-producing *E. coli* host, since there are relatively fewer contaminants and the protein can be recovered without damaging its cellular source. There have been various attempts at developing such a system, for excreting proteins to the medium, all of which include some tactic for overcoming the integrity of the outer membrane barrier.

One approach generally involves genetically engineering *E. coli* to co-express the desired protein in secretable form (bearing a signal peptide) together with a lytic protein which affects outer membrane integrity to the extent that it becomes permeable or "leaky" (see U.S. 4,595,658 in which the gene III product of the ϕ phage is used as the permeabilizing agent; Kobayashi et al, J. Bacteriol. June 1986, pp 728-732 in which activation of the cryptic *kil* protein is used; and see EP 140,864 in which a temperature sensitive lysogen is used). In these methods, careful control of lytic product expression is required to maintain host viability. Moreover, co-expression per se can be an energy drain on the host, reducing yield of the desired protein and reducing host cell biomass.

In another approach, the desired protein is expressed as a chimeric protein, in which the desired protein is fused to a carrier protein. The carrier proteins typically used are those naturally produced *E. coli* proteins, or fragments thereof, which are capable of being excreted (hemolysin) or which are bound to the outer membrane (*ompF*). For example, Mackman et al found that *ompF*, without its signal peptide, could be dragged through the *E. coli* envelope to the medium when fused with a C-terminal portion of hemolysin (EMBO J. Vol 6, No. 9, pp. 2835-2841, 1987). Nagahari et al found that human β -endorphin was released to the medium when fused with at least of the *E. coli ompF* protein (EMBO J. Vol 4, No. 13A, pp. 3589-3592, 1985). To recover proteins produced by such techniques, however, the desired protein must be cleaved from the carrier protein, which makes isolation difficult.

Yet another approach makes use of *E. coli* strains in which the integrity of the outer membrane has been compromised at the genetic level. Such strains, known as "leaky" hosts, are incapable of retaining periplasmic proteins. In practice, these strains are difficult to maintain in a viable condition without stringent control of environmental conditions.

It is an object of the present invention to provide a method enabling heterologous proteins to be excreted to the culture medium in which the protein-producing *E. coli* host is grown.

It is an object of the present invention to provide a DNA vector enabling excretion from *E. coli* of a heterologous protein encoded thereon.

It is a further object of the invention to provide an *E. coli* strain that has been genetically engineered to express a desired heterologous protein which is excreted to the medium in which the *E. coli* strain is cultured.

It is an overall object of the present invention to facilitate recovery of *E. coli*-produced, heterologous proteins by enabling accumulation of those proteins in the *E. coli* culture medium.

SUMMARY OF THE INVENTION

It has now been found that the excretion of heterologous proteins from *E. coli* hosts can be achieved, consistently and for a wide variety of heterologous proteins, without assistance from carrier proteins or membrane-lytic agents and by using "healthy" hosts rather than mutant strains having defective outer membranes. More particularly it has been found that heterologous proteins expressed from DNA vectors as herein described are excreted directly into the culture medium and are recoverable therefrom in relatively

significant yields.

In accordance with one aspect of the present invention, there is provided a recombinant DNA construct useful for obtaining excretion from *E. coli* of a heterologous protein, comprising a coding region in which DNA coding for a heterologous protein is coupled in reading frame with DNA coding for the *ompA* signal peptide to enable secretion of the protein to be periplasmic; and a control region linked operably with the coding region to enable expression thereof wherein the control region comprises the *tac* promoter, the *lac* operator and a consensus ribosome binding site. The recombinant DNA construct is preferably incorporated on a vector, to form an *E. coli* excretion vector using for creating *E. coli* transformants that excrete heterologous proteins.

In accordance with another aspect of the invention, there is provided an *E. coli* host which excretes a heterologous protein into the medium in which the host is cultured as a result of having been transformed by the recombinant DNA construct of the invention, as characterized above. According to preferred embodiments of this aspect of the invention, *E. coli* cells are provided that are capable of excreting mammalian proteins or fragments thereof.

According to another aspect of the invention, there is provided a method for producing a heterologous protein which comprises culturing a transformed *E. coli* strain of the invention in a culturing medium and then recovering the heterologous protein directly from the medium in which the strain has been cultured. In particularly preferred embodiments of this aspect of the invention, the method is applied for the production of such human proteins as parathyroid hormone (PTH), epidermal growth factor (EGF), interleukin-6 (IL-6) and soluble CD4 (the extracellular domain of a T-cell membrane protein).

Using the system herein described, relatively large amounts of heterologous protein are excreted to the culture medium, thereby providing not only for a simplified protein recovery process but also providing the protein in significant yield. The present excretion system is unencumbered by requirements known in other prior art systems: excretion resulting from the present system is direct, occurs in the absence of cell lysis, and is consistently reproducible within non-restrictive parameters hereinafter described.

REFERENCE TO DRAWINGS

Figure 1 provides the nucleotide sequence and a schematic representation of a recombinant DNA construct useful in accordance with the invention. Solid, horizontal lines identify the four synthetic oligonucleotides used to assemble the construct;

Figure 2 illustrates the incorporation of the *Tac* construct into a derivative of the plasmid pUC18, designated pE, to form the plasmid pETac;

Figure 3 illustrates construction of a *Tac*-containing plasmid which also incorporates the *C. fimi* *cenA* gene, to form pcenATac;

Figure 4 illustrates the incorporation into pETac of DNA coding for human parathyroid hormone (PTH), to form pETacPTH;

Figure 5 illustrate the incorporation into pETac of DNA coding for human epidermal growth factor (EGF), to form pETacEGF;

Figure 6 illustrates incorporation of DNA coding for interleukin-6 (IL-6) into the vector pcenATac to form pcenATacIL6.

Figure 7 illustrates incorporation of DNA coding for an extracellular domain of CD4 into plasmid pcenATac to form pcenATacCD4;

Figure 8 illustrates schematically the incorporation of a '*par*' element into a variant of pETacPTH; and

Figure 9 illustrates schematically the incorporation of the *lacP* gene into the *par*-containing variant of pETacPTH illustrated in Figure 8.

DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS

This invention relates to a system for producing heterologous proteins in the host *E. coli*, whereby such proteins are excreted to the medium in which the host is cultured.

By the term "heterologous protein" is meant a protein which, although not naturally produced by *E. coli*, is expressed by this host when suitably transformed with DNA coding for the protein, such as genomic DNA, cDNA and synthetic DNA. Among the heterologous proteins that may be produced using the system herein described, naturally secreted mammalian proteins including those of human origin are preferred, particularly those protein species having therapeutic value such as growth factors, lymphokines, hormones, interferons, enzymes and the like. Moreover, there appears to be no restrictive limit on the size of protein that can be excreted using the present system, although proteins exceeding about 100kD may be excreted at lower than preferred levels. Most suitably, proteins produced using the present system are those proteins having a molecular weight in the range from about 5 to 50 kD.

It will be appreciated as well that, although the production of mature proteins may be preferred, in order to allow direct isolation from the medium of the authentic form of the protein, hybrid proteins may also be produced and excreted in accordance with the invention as may fragments of the authentic protein. Hybrid proteins may include authentic proteins bearing additional amino acid residues which enhance, or at least do not detract from, the biological activity of the authentic protein. Fragments of authentic proteins may include biologically active domains of the authentic protein.

Although originally designed to enable large amounts of heterologous protein to be secreted to the

periplasm of an *E. coli* host, with the full expectation that the protein would accumulate in and require recovery from the periplasm, it was surprisingly found that the DNA construct illustrated in Figure 1 is capable of causing excretion of heterologous protein to the medium. The components of the construct are, in fact, associated in a manner typical of *E. coli* secretion vectors. That is, a control region which includes a promoter, operator and ribosome binding site is linked with a coding region having DNA coding for an *E. coli*-recognized signal peptide located upstream of a multiple cloning site for incorporation of DNA coding for a desired heterologous protein to enable secretion of the heterologous protein to the periplasm. By selecting from among the available components these with superior efficiency, however, constructs have been developed that enable the heterologous protein coded thereon to be excreted to the medium in which the *E. coli* host is cultured.

The most preferred recombinant DNA construct is illustrated in Figure 1 to which reference is now made. To produce this construct, the four single-stranded oligonucleotides identified by horizontal lines on Figure 1 were individually synthesized by the phosphoramidite method. The gel-purified oligonucleotides were then assembled by annealing and gaps were filled in with the aid of DNA sequenase, to provide the double-stranded construct as illustrated. Thus, the construct was prepared using standard gene synthesis methodology, as described for example by Wosnick et al in *Gene*, Vol 60, pp 115-127, 1987.

As depicted in Figure 1, the construct comprises the hybrid tac promoter, the lac operator, a consensus ribosome binding site, *ompA* signal peptide-encoding DNA, a multiple cloning site, translational stop codons in all three reading frames and a transcriptional termination region associated relative to each other according to the nucleotide sequence indicated. The construct illustrated in Figure 1 incorporates the transcriptional terminator of the *E. coli trpA* gene, although it will be appreciated that other transcriptional terminators may be employed in its place, such as those associated with the *thr*, *his* and *phe* genes of *E. coli*. Nucleotide sequences of these terminators are provided by Rosenberg and Court in *Ann. Rev. Genet.*, 1979, Vol.13, 319-355. The construct illustrated in Figure 1 is provided also with flanking restriction sites for convenient ligation into a suitable *E. coli* vector, or into phage vectors such as M13mp18, in which sequencing and site-specific mutagenesis may be performed.

To provide for protein excretion, the construct, hereinafter designated simply as Tac, may be incorporated on any of the commercially available *E. coli* vectors to enable it to be introduced and stably maintained in *E. coli*. Although phage vectors can be employed, plasmid vectors are preferred. The pUC series of plasmids are particularly suitable. So that the restriction sites within the multiple cloning site of the Tac cassette remain unique, however, common sites in the selected vector are preferably deleted. Once incorporated on a suitable vector, the resulting plasmid may be amplified in *E. coli* to provide amounts sufficient for subsequent cloning work.

It will be appreciated that DNA coding for the selected heterologous protein is conveniently incorporated on the plasmid within the multiple cloning sites provided thereon, using standard cloning/ligation methods. To incorporate protein-encoding DNA into the construct, the cloning site and cloning technique are selected to enable the protein-encoding DNA to be incorporated in reading frame with the *ompA* signal-peptide encoding DNA. To enable the *ompA* signal peptide and heterologous protein to be fused directly when expressed, without intervening amino acid residues that are superfluous, the fusion junction may be tailored by site-specific mutagenesis using, for example, the technique generally described by Kunkel, *Proc. Natl. Acad. Sci. USA*, Vol 82, pp. 488-492, 1985. The same technique may, also be used to remove portions of the heterologous protein-encoding DNA, for example to enable fragments of the protein to be expressed.

Once DNA coding for the desired heterologous protein is incorporated on the excretion vector, a selected *E. coli* strain is transformed therewith using standard methods.

E. coli strains useful as hosts include commercially available "healthy" strains. Strains characterizable as healthy are those strains which, when cultured under normal conditions, do not release periplasmic proteins or cytoplasmic proteins to the medium in which they are grown. For example, when cultured in standard growth medium, the medium in which suitable strains are grown should not contain detectable amounts of either β -galactosidase or β -lactamase (for strains that naturally produce these proteins as cytoplasmic and periplasmic proteins, respectively). Because the Tac construct (Fig. 1) from which the desired heterologous protein is expressed makes use of the tac promoter and lac operator, as described in more detail hereinafter, the transformed host strain should be capable of expressing, preferably over-producing, the *lacI* product so that expression of the heterologous protein can be regulated. The need for *lacI* overproduction by the *E. coli* transformant can be met, according to one embodiment of the invention, by using *E. coli* hosts that already harbour the *lacI*^q gene responsible for overproduction of the *lacI* product. *LacI* over-producing strains that may be employed as host include the JM series of *E. coli* strains available from Clontech Laboratories Inc., California, USA. Specific host strains suitable for use include JM 103 and JM105 (JM 109, a *recA* host should be avoided since it may be subject to lysis). Preferred for use herein is the strain JM 101.

The need for *lacI* overproduction in the transformant may alternatively be met by incorporating the *lacI*_q gene on the Tac excretion vector. Since, in this situation, the over-production of *lacI* is mediated by the Tac excretion vector any of a variety of commercially available *E. coli* strains may be employed as host, including such strains as DH1, RR1, C600, CMK603 and EB505. The *lacI*^q gene to be incorporated on the Tac excretion vector may be obtained as a 1.2 kb HindIII fragment of plasmid pMMB22 (described by Bagdasarian et al in *Gene* 26,273-282, 1983) and then incorporated non-disruptively at any site on the plasmid vehicle containing the Tac construct.

To enhance the stability of inheritance of the plasmid from the strain originally transformed to its progeny, a partition element (*par*) functional in *E. coli* may also be incorporated on the Tac excretion vector. The nature and location of one such *par* element, contained on *E. coli* plasmid pSC101, is described by Miller et al in Gene 24, 309-315, 1983. This *par* element may be liberated from pSC101 as a 380bp HincII/AvaI fragment and then cloned into a suitable site on the Tac excretion vector.

Following transformation, *E. coli* strains harbouring the excretion vector are cultured in a culturing medium most appropriate for the selected host. Generally, LB broth or 2YT medium (yeast extract/tryptone) can be used to culture those strains herein preferred. Selective pressure should be maintained by providing a metabolite required for survival of the transformant. When pUC-based excretion vectors are used, for example, the medium should contain ampicillin. Ampicillin concentrations of around 70ug/ml are suitable.

The tac promoter on the construct is regulatable, as mentioned above, through binding of the *lacI* gene product to the lac operator located adjacent the tac promoter. Binding of *lacI* product represses the tac promoter, lowering expression levels of coding DNA under its control. To raise expression levels, the chemical IPTG (isopropyl-β-D-thiogalactopyranoside), which binds the *lacI* and de-represses the tac promoter, is typically added to the culture medium to raise expression levels, in this circumstance. In accordance with a preferred embodiment of the invention, transformants are cultured in the absence of IPTG. It has been found that yield of excreted protein is not significantly different, and can actually be enhanced when IPTG is not used in the culture medium. Alternatively, IPTG may be added to the medium, preferably when the cells have reached early log growth phase.

Whereas expression from the tac promoter is known to be more efficient at around 37°C, it has been found that lower temperatures can be used without significant yield sacrifice. In accordance with a preferred embodiment of the invention, transformants are cultured at around 30°C i.e. 28-32°C. An advantage of working at the lower temperature is, of course, enhanced stability of protein and plasmid copy number.

To determine the optimum time period for which cultures should be grown to realize maximum yield of excreted protein, trials can be conducted and excreted protein assayed in a time-course experiment. In general, it is possible, with the present system, to recover reasonable yields of protein once cells reach early-log phase, although greater amounts of protein can be expected to accumulate in the medium without about 4-10 hours thereafter.

Excretion of the protein to the culture medium greatly facilitates recovery and isolation of the protein. The culture medium can be siphoned from the bioreactor if desired, provided that fresh nutrients are returned to the system. Protein contained in the spent medium can be isolated using biochemical techniques that reflect the nature of the protein in terms of its molecular size, net charge, isoelectric point, etc. The medium may be concentrated first such as by lyophilization. Further, when antibodies are available or a natural ligand for the protein is available, affinity columns may be used.

Specific embodiments of the invention are now exemplified with reference to the drawings.

EXAMPLE 1 - Construction of *E. coli* excretion vectors

Two excretion vectors were constructed, by incorporating the Tac construct illustrated in Figure 1 are prepared as previously described, on *E. coli* plasmids containing an origin of replication and a selectable marker. One plasmid vector, designated pETac and shown in Figure 2, was constructed by incorporating the Tac construct into the NdeI site of plasmid pE, a variant of pUC18 lacking the multiple cloning sites, except EcoRI.

A second plasmid vector, designated pcenATac was formed as illustrated in Figure 3 by incorporating the Tac construct between the KpnI/HindIII sites on plasmid pUC 18-1.6 *cenA* described by Guo et al., FEMS Microbiol. Lett. Vol. 49, pp. 279-283, 1988 which is herein incorporated by reference. The *cenA* portion of pUC 18-1.6 *cenA* that is also incorporated on excretion vector pcenATac is capable of expressing *Cellulomonas fimi* endoglucanase. The expressed endoglucanase is excreted when expressed by an *E. coli* plasmid, as reported by Guo et al., *supra*, resulting consequentially in the release of *E. coli* proteins from the periplasm to the culture medium. Based on these prior observations, it was originally postulated that the *cenA* gene product could be used to facilitate release of heterologous proteins secreted by *E. coli* to the periplasm. While this may be possible, the evidence presented later in these examples demonstrates that expression of the *cenA* gene product is not required to obtain excretion of heterologous proteins from an *E. coli* host when vectors containing the Tac construct are employed. The Tac construct is sufficient *per se* to excrete a selected heterologous protein encoded thereon. In this light, therefore, it is to be understood that the two excretion vectors described above and used in the examples are substantially the same in the present context. The co-existence of the *cenA* gene on pcenATac is irrelevant to the proper functioning of the Tac construct, and to the extracellular release of proteins expressed from it.

EXAMPLE 2 - Cloning of heterologous protein-encoding DNA

DNA coding for various proteins of mammalian origin was incorporated into either of the two expression vectors described in Example 1, using strategies indicated in the referenced drawings:

PTH:

In its mature form, PTH is an 84-amino acid peptide that acts in humans to raise blood calcium and increase bone resorption. DNA coding for a PTH analogue, bearing an N-terminal methionine residue was synthesized

using the general method described by Wosnick et al, *supra*, and according to the nucleotide sequence published by Hendy et al., Proc. Natl. Acad. Sci. U.S.A., Vol. 78 pp. 7365-7369, 1981. As indicated in Figure 4, the synthetic Met PTH-encoding DNA was obtained as an EcoRI/HindIII fragment from plasmid pKK223-PTH and cloned, by blunt-end ligation, into the SphI site of excretion vector pETac, in the manner outlined in the drawing, to form plasmid pETacPTH. In the resulting plasmid, two artefactual amino acid residues are encoded between the ompA signal peptide and Met-PTH.

EGF:

In its mature form, human EGF is a 53-amino acid peptide having the amino acid sequence indicated by Bell et al., *infra*. EGF has a variety of therapeutic utilities, including inhibition of gastric acid secretion. Based on the nucleotide sequence published by Bell et al., Nucleic Acids Research, Vol. 14, pp 8427-8446, 1986, an EcoRI/XbaI cassette of EGF-encoding DNA was prepared and cloned previously into pUC12. To clone the EGF-encoding DNA into an *E. coli* excretion vector, the EGF gene was retrieved from pUC12 and force cloned into StuI/XbaI - digested pETac as indicated in Figure 5, to produce pETacEGF. In the resulting plasmid, four intervening amino acid residues are encoded between the *ompA* signal and the N-terminus of EGF (Figure 5).

INTERLEUKIN-6:

DNA coding for mature interleukin-6, a human protein having numerous and wide ranging physiological activities, was purchased from British Biotechnology Limited (cat # BBG-17). The nucleotide sequence of the IL-6 encoding DNA was as reported by Hirano et al. in Nature, Vol. 324, pp. 73-76, 1986; (see also WO 88/00206). The synthetic DNA construct was then ligated into the NruI site of the Tac construct contained on pcenATac as illustrated in Figure 6, to form plasmid pcenATacIL6.

EXTRACELLULAR DOMAIN OF CD4:

CD4 is a membrane-bound protein found on human T-cells that is recognized by the AIDS virus and is believed therefore to be involved in the mechanism by which the virus invades these cells. An extracellular domain of CD4 is that portion of the CD4 molecule that extends from the cell membrane into the extracellular environment (this region is also known as "soluble" CD4). DNA coding for the major portion of the CD4 extracellular domain i.e. CD4 3-369, was obtained based on the CD4 amino acid sequence published by Maddon, P.J. et al., Cell, Vol. 42, pp. 93-104, August 1985 and previously cloned into the yeast secretion vector pMV2Adel (Wong et al., Bio/Technology, Vol. 6, pp. 713-719, 1988). The CD4 DNA was liberated from the yeast vector and force cloned into the SphI/EcoRV site on pcenATac, as illustrated in Figure 7, to form pcenATacCD4. In the resulting plasmid, the *ompA* signal and CD4 are spaced by nine codons incorporated from the yeast vector source of the CD4 DNA.

In each of the plasmids constructed as described above, DNA coding for a mammalian protein has been incorporated in reading frame with the *ompA* signal to enable secretion of the protein to the *E. coli* periplasm. This coding region is, in each case, under the expression control of a control region containing the tac promoter, lac operator and consensus ribosome binding site.

In separate experiments, the plasmids were introduced into *E. coli* strain JM 101 using standard methods and the transformants cultured according to the protocols indicated more precisely below in order to characterize the location of the heterologous proteins expressed.

EXAMPLE 3 - Excretion of Heterologous (Human) Proteins by *E. coli*

PTH:

JM 101 transformants containing the PTH excretion vector pETacPTH were cultured overnight at 30°C in LB broth containing ampicillin and then inoculated into fresh medium, with continued culturing at 30°C until reaching an optical density of 0.3 as measured at OD600 (early log phase). Cultures were then induced (1mM IPTG). At two hour growth intervals, aliquots of culture were withdrawn and fractionated to produce samples of (1) culture medium to identify excreted products; (2) osmotic shock fluid to identify periplasmic proteins; and (3) sonicated lysate which contains both cytoplasmic proteins and thus provides an indication of the cytoplasmic protein content by comparison with the shock fluid results. In particular, each fraction was assayed to detect PTH, β -lactamase (a native periplasmic protein) and β -galactosidase (a native cytoplasmic protein) and to measure total protein content. Non-induced cultures were also run for comparison. The results of these trials are provided in Table 1 below:

Table 1
Determination of Protein Concentration and Enzymatic Activities in Various Fractions of *E. coli* Culture Expressing hPTH

A Results for Induced Culture

Hr. After IPTG Induction at O.D. ₆₀₀ = 0.3	Protein Conc. ¹ mg/L		hPTH Conc. ² mg/L		β-lactamase 3 Activity U/L			β-galactosidase ⁴ Activity U/L		
	C ⁵	P ⁶	S ⁷	C	P	S	C	P	S	P
0	11	2.9	21	0	0	1.54	3.0	0.3	4	0.68
2	16	3.5	21	0.13	0.1	1.0	4.0	3.4	8.5	0.18
4	11	6.7	21	0.38	0.07	2.1	8.0	2.9	16	0.68
6	302	9.7	27	1.0	0.02	2.3	1.9	4.7	28	2.28
8	208	5.8	24	0.38	0.02	6.2	2.0	2.9	21	3.88
10	214	6.1	32	0.39	0.01	25.4	2.8	2.9	27	5.50
12	396	8.5	39	0.32	0.01	15.1	3.0	2.3	34	7.4
14	295	11.9	31	0.4	0.02	19.6	2.8	4.3	38	8.3
16	294	11.8	ND	0.4	0.01	ND	2.0	4.6	34	10.7
24	552	16.1	ND	0.44	0.01	ND	0	5.8	61	23.3

B Results for Non-Induced Culture

Hr. After Growth Reached at O.D. ₆₀₀ = 0.3	Protein Conc. mg/L		hPTH Conc. mg/L		β-lactamase Activity U/L			β-galactosidase Activity U/L		
	C	P	S	C	P	S	C	P	S	P
6	99	6	23	6.4	0.05	5	20.2	79	58	4.5
12	285	7.5	20	4.4	0.1	10	39	20	75	2.7
24	564	18.7	31	1.9	0.02	17	7.4	47	96	2.2

See Legends for descriptions of superscripts 1, 2, 3, 4, 5, 6 and 7 respectively.

Table 1 Legends

¹Measured by the Bio-Rad protein assay using bovine serum albumin to provide the standard curve.

²Determined by radioimmunoassay N-tack kit (Incstar # 10412, Catalog # 96065).

³Assayed spectrophotometrically using nitrocefin as the substrate (Antimicrob. Ag. Chemother. Vol. 1, pp. 283-288, 1972). 1U of β -galactosidase produces 1 nmol of nitrocefoic acid per min.

⁴Assayed according to Miller (Experiments in Molecular Genetics, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1972). 1U of β -galactosidase produces 1 nmol of *o*-nitrophenol per min.

⁵C stands for total cell lysate generated by sonication.

⁶P stands for periplasmic fraction generated by osmotic-shock technique (J.Biol. Chem. Vol. 241, pp. 3055-3062, 1966).

⁷S stands for culture supernatant. ND : Not Determined.

Several significant findings are revealed in Table 1. Firstly, it is clear that PTH was excreted to the culture medium. That β -galactosidase was not detected in the culture medium indicates that the appearance of PTH in the medium was not a consequence of cell lysis. Further, the appearance of the periplasmic protein β -lactamase, in the medium, indicates that release of PTH from the periplasm is non-specific. The results obtained from similar assays of the non-induced culture i.e. cultures to which IPTG was not added, are consistent with the induced culture assays in those respects noted above, but it should be noted that yield of excreted PTH is not significantly depressed in the absence of IPTG. This is a particularly surprising finding in that IPTG is known to prevent the *lacI* product from repressing the *tac* promoter. Accordingly, in the absence of IPTG and the presence of the *lacI* product, depressed levels of PTH are to be expected. Either method is capable of producing PTH in relatively good yield, with maximum yields being realised about 10 hours after the culture has reached early log phase.

EGF:

E. coli JM 101 transformants containing the EGF excretion plasmid pETacEGF were evaluated in substantially the same manner as described above for PTH. The results, as indicated in Table 2 below, mirror those of the PTH transformant:

Table 2
Determination of Protein Concentration and Enzymatic Activities in Various Fractions of *E. coli* Culture Expressing hEGF

A Results for Induced Culture														
Hr. After IPTG Induction at O.D. ₆₀₀ = 0.3	Protein Conc. ¹ mg/L			hEGF Conc. ² mg/L			β-lactamase 3 Activity U/L			β-galactosidase ⁴ Activity U/L				
	C ⁵	P ⁶	S ⁷	C	P	S	C	P	S	C	P	S		
0	16	2	16	2	0	5	9.1	0.4	14.4	2.6	Not Detectable			
2	32	3	31	5	1	2	16.8	0.3	71	2.1				
4	32	4	32	3.5	2	4	12.8	0.45	72	2.1				
6	85	4	32	3	0	30	13.5	0.42	80	2.9				
8	140	5	28	2.5	0.5	27	13.7	0.37	79	6.2				
10	285	6	25	2	0.5	32	7.6	0.33	77	2.0				
12	224	6	27	3	0	29	7.4	0.4	81	1.1				
14	272	5	25	3.5	0	28	6.5	0.52	78	2.3				
16	413	8	27	3.5	0	23	5.7	0.55	82	0.6				
24	362	11	32	2	0.5	33	1.1	1.1	72	13.3				

B Results for Non-Induced Culture														
Hr. After Growth Reached at O.D. ₆₀₀ = 0.3	Protein Conc. mg/L			hEGF Conc. mg/L			β-lactamase Activity U/L			β-galactosidase ⁴ Activity U/L				
	C	P	S	C	P	S	C	P	S	C	P	S		
6	105	14	21	17	0	13	39.8	19.6	5.8	0.52	Not Detectable			
12	144	9	35	15	2	23	34.9	9.5	19	0.52				
24	144	20	60	10	0	90	6.3	0.8	32	3.7				

²Determined by radioimmunoassay kit (Amersham, Code 1M 1961).

See Legends to Table 1 for descriptions of superscripts 1, 3, 4, 5, 6 and 7 respectively.

The tabulated data reveals that EGF was excreted to the culture medium but not as the β -galactosidase data shows, as a result of cell lysis. With induction by IPTG, EGF production at 4 hours was significant with maximum yields being realized about 10 hours after the culture reached mid-log phase. Again, the data reveals that IPTG induction is not essential. The absence of IPTG effect may result from the combined effect of the strong tac promoter and consensus ribosome binding site which is too strong to be counteracted by the *lacI* product which normally represses tac function. As a further observation, it will be noted that excretion of EGF from the periplasm is remarkably complete.

CD4:

E. coli strain JM 101 harbouring the CD4 excretion plasmid pcenATacCD4 was cultured in the same manner described above and induced with IPTG after the culture reached early log phase. Aliquots were taken at two hour intervals and the medium analyzed after dialysis, lyophilization and reconstitution in phosphate-buffered saline containing 0.02% NaN₃ and 1mM PMSF (an inhibitor of protease degradation). Samples were assayed for CD4 activity in a sandwich ELISA format using the commercially available anti-CD4 antibodies OKT4.2 as capture and OKT4-urease as conjugate. The results of the assay of the culture medium are tabulated below:

TABLE 3
Determination of CD4 Activity

Hrs after induction	Culture Induction (30°C)	Culture Induction (37°C)
	O.D. 590	
2	0.218	0.226
4	0.377	0.335
6	0.268	0.229
8	0.316	0.218
10	0.247	0.276

*Values are corrected to reflect background (control - host/vector only).

It is significant to note that CD4 was excreted at both temperatures. At 30°C, the *cenA* product is not capable of leaking to any significant extent (see Guo et al., *supra*). Thus, the *cenA* product cannot reasonably be assumed to be responsible for CD4 leakage into the medium.

IL-6:

In preliminary experiments in which the culture medium of JM 101 transformants harbouring the IL-6 excretion plasmid were assayed, strongly positive assay results have been obtained. Specifically, 250 units of IL-6 activity/ml of medium were detected using the bioassay described by Koj et al, 1986, J. Immunol. Methods, 76, pp.317-327.

While the heterologous proteins produced by the respective plasmids exemplified above are unlikely to be "mature" in the sense that the N-terminus of the excreted protein is not authentic, it will be appreciated that these plasmids can be mutated site-specifically to remove DNA coding for superfluous N-terminal amino acid residue and allow the N-terminus of the mature protein to be fused directly with the C-terminus of the *ompA* signal peptide. Reference may be made to Kunkel et al, *supra*, for details on this procedure. Systems useful for performing oligonucleotide-directed mutagenesis conducting site-specific mutagenesis are also sold commercially in kit form by Amersham International plc. In the specific case of the PTH excretion vector, pETacPTH, the mutagenesis technique can be employed to produce various forms of the PTH molecule fused directly to the *ompA* signal peptide when expressed i.e. PTH1-84, and PTH1-34.

Example 4 - Modification of Tac excretion vector

A version of the pETacPTH plasmid, in which DNA coding for PTH1-84 had been brought, by site-specific mutagenesis, into direct fusion with DNA coding for the *ompA* signal was modified by incorporating thereon both the *lacR* gene and a *par* element. To obtain the *par* element, *E. coli* plasmid pSC101 (Miller et al., *supra*) was cleaved with HincII and SmaI, thereby releasing a 2.9kb fragment which was then cleaved by Aval. The resulting 380bp HincII/Aval fragment harbouring the *par* element was then cloned, after gel purification, into the HindIII site immediately downstream of the Tac cassette, by blunt-end ligation. Construction of the resulting plasmid, designated par8, is illustrated in Figure 8.

The *lacR* gene was then cloned into plasmid par8, using the strategy illustrated schematically in Figure 9. To obtain the *lacR* gene, the broad host range plasmid pMMB22 (described by Bagdasarian et al, *supra*) was cleaved with HindIII. A gel-purified 1.2kb fragment harbouring the *lacR* gene was then cloned, by blunt-end

ligation, into PvuII-restricted plasmid par 8 i.e. incorporated upstream of the Tac cassette.

The performance of the resulting plasmid, which harbours the *par* element, the *lac^R* gene and the Tac/PTH cassette, was then evaluated in a variety of *E. coli* host strains. To assess performance of the *lac^R* component of the modified plasmid, wild type *E. coli* strains, lacking the *lac^R* genotype, were transformed. In all strains tested, including DH1, RR1, C600, CMK603 and EB505, bioactive PTH activity was detected following induction with IPTG, indicating that the product of the plasmid-encoded *lac^R* gene was functional. Functional *par* activity was also detected in JM101 transformants. Incorporation of the *par* element resulted in stable inheritance of the plasmid throughout many generations, even in the absence of selective pressure.

Claims

1. A recombinant DNA construct useful for obtaining excretion from *E. coli* of a heterologous protein, said construct comprising a coding region in which DNA coding for the heterologous protein is coupled in reading frame with DNA coding for the OmpA signal peptide to enable secretion of the protein to the periplasm; and a control region linked operably with the coding region to enable expression thereof in an *E. coli* host, said control region comprising the tac promoter, the lac operator and a consensus ribosome binding site.
2. An *E. coli* excretion vector useful for producing *E. coli* transformants that excrete heterologous protein, wherein said vector comprises a recombinant DNA construct as defined in claim 1.
3. The vector according to claim 2 wherein the heterologous protein encoded thereon is a mammalian protein.
4. The vector according to claim 3 wherein the heterologous protein is human PTH or a fragment thereof.
5. The vector according to claim 3 wherein the heterologous protein is human interleukin-6.
6. The vector according to claim 3 wherein the heterologous protein is an extracellular domain of CD4.
7. The vector according to claim 3 wherein the heterologous protein is human EGF.
8. The vector according to claim 4 wherein the heterologous protein is human PTH.
9. An *E. coli* excretion vector as defined in claim 2 which further comprises the *lac^R* gene.
10. An *E. coli* excretion vector as defined in claim 2 which further comprises a *par* element.
11. An *E. coli* strain which excretes a heterologous protein to the medium in which the strain is cultured as a result of having transformed by an excretion vector as defined in claim 2.
12. An *E. coli* strain which excretes human PTH or a fragment thereof to the medium in which the strain is cultured as a result of having transformed by an excretion vector as defined in claim 4.
13. An *E. coli* strain which excretes human interleukin-6 to the medium in which the strain is cultured as a result of having transformed by an excretion vector as defined in claim 5.
14. An *E. coli* strain which excretes an extracellular domain of CD4 to the medium in which the strain is cultured as a result of having transformed by an excretion vector as defined in claim 6.
15. An *E. coli* strain which excretes human EGF into the medium in which the strain cultured as a result of having transformed by an excretion vector as defined in claim 7.
16. A method for producing a heterologous protein which comprises culturing an *E. coli* strain as defined in claim 11 in a culturing medium and then recovering the heterologous protein directly from the medium in which the strain has been cultured.
17. The method according to claim 16 wherein the host is cultured at about 30°C.
18. The method according to claim 16 wherein the host is cultured in the absence of IPTG.
19. A method for producing human PTH which comprises culturing an *E. coli* strain as defined in claim 12 in a culturing medium and then recovering human PTH directly from the medium in which the strain has been cultured.
20. A method for producing human EGF which comprises culturing an *E. coli* strain as defined in claim 15 in a culturing medium and then recovering human EGF directly from the medium in which the strain has been cultured.

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7






FIG. 8





(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 357 391 A3

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 89308753.6

(51) Int. Cl.⁵: **C12N 15/70**, C12N 1/21,
C12P 21/02, C12N 15/16,
//(C12N1/21,C12R1:19)

(22) Date of filing: 30.08.89

(30) Priority: 31.08.88 US 239145
18.08.89 US 395797

(43) Date of publication of application:
07.03.90 Bulletin 90/10

(64) Designated Contracting States:
AT BE CH DE ES FR GB IT LI NL SE

(68) Date of deferred publication of the search report:
31.07.91 Bulletin 91/31

(71) Applicant: **Allelix Biopharmaceuticals Inc.**
6850 Goreway Drive
Mississauga Ontario, L4V 1P1(CA)

(72) Inventor: **Wong, Raymond W. K.**
6903 Edenwood Drive
Mississauga Ontario L5N 4V6(CA)
Inventor: **Sutherland, Margaret L.**
3700 Kaneff Cres. Apt. 2312
Mississauga Ontario L5N 4B8(CA)


(74) Representative: **Hildyard, Edward Martin et al**
Frank B. Dehn & Co. European Patent
Attorneys Imperial House 15-19 Kingsway
London WC2B 6UZ(GB)

(54) Excretion of heterologous proteins from E. Coli.

(57) A recombinant DNA construct useful for obtaining excretion from *E. coli* of a heterologous protein, said construct comprising a coding region in which DNA coding for the heterologous protein is coupled in reading frame with DNA coding for the OmpA signal peptide to enable secretion of the protein to

the periplasm; and a control region linked operably with the coding region to enable expression thereof in an *E. coli* host, said control region comprising the tac promoter, the lac operator and a consensus ribosome binding site.

FIG. 1



EP 0 357 391 A3



European
Patent Office

EUROPEAN SEARCH REPORT

Application Number

EP 89 30 8753

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
X	WO-A-8 803 171 (SYNERGEN BIOLOGICALS, INC.) * Page 27, lines 23-30; page 30, line 36 - page 31, line 3 *	1,2,3,11, 16	C 12 N 15/70
Y	-----	4,5,7,8,9, 10,12,13, 15,19,20	C 12 N 1/21 C 12 P 21/02 C 12 N 15/16 // (C 12 N 1/21 C 12 R 1:19)
X	WO-A-8 603 519 (SYNERGEN BIOLOGICALS, INC.) * Page 39, lines 2-10,19-26 *	1,2	
P,X	JOURNAL OF BIOTECHNOLOGY, vol. 11, no. 1, July 1989, pages 11-23, Amsterdam, NL; A. VAN KIMMENADE et al.: "Secretion of murine and human interleukin-2 by Escherichia coli" * Page 14, lines 9-12; page 18, lines 16-22 *	1,2,3	
Y	J. BIOL. CHEM., vol. 263, no. 3, 25th January 1988, pages 1307-1373, Baltimore, US; S.A. RABBANI et al.: "Recombinant human parathyroid hormone synthesized in Escherichia coli" * Abstract *	4,8,12,19	
Y	WO-A-8 800 206 (SYNERGEN BIOLOGICALS, INC.) * Page 14, line 17 - page 16, line 32 *	5,13	TECHNICAL FIELDS SEARCHED (Int. Cl.5)
Y	AGRIC. BIOL. CHEM., vol. 51, no. 4, 1987, pages 1099-1104, Tokyo, JP; T. OKA et al.: "Efficacies of different secretion vectors for secretion of human epidermal growth factor by Escherichia coli" * Abstract *	7,15,20	C 12 N C 07 K
Y,D	GENE, vol. 26, 1983, pages 273-282, Amsterdam, NL; M.M. BAGDASARIAN et al.: "Activity of the hybrid trp-lac(tac) promoter of Escherichia coli in Pseudomonas putida. Construction of brad-host-range, controlled-expression vectors" * Summary *	9	
	----- -/-		
The present search report has been drawn up for all claims			
Place of search		Date of completion of search	Examiner
The Hague		23 April 91	THIELE U.H-C.H.
CATEGORY OF CITED DOCUMENTS			
X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention		E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons ----- &: member of the same patent family, corresponding document	



European
Patent Office

EUROPEAN SEARCH REPORT

Application Number

EP 89 30 8753

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
Y,D	GENE, vol. 24, 1983, pages 309-315, Amsterdam, NL; C.A. MILLER et al.: "Nucleotide sequence of the partition locus of Escherichia coli plasmid pSC101" * Summary * - - - - -	10	
			TECHNICAL FIELDS SEARCHED (Int. Cl.5)
The present search report has been drawn up for all claims			
Place of search		Date of completion of search	Examiner
The Hague		23 April 91	THIELE U.H-C.H.
CATEGORY OF CITED DOCUMENTS X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons &: member of the same patent family, corresponding document			

THIS PAGE BLANK (USPTO)